ALKOVE Clinical Trial, a 4th Generation TKI from Nuvalent

The Phase 1/2 trial of Nuvalent, Inc.’s NVL-655, the fourth generation ALK TKI, has begun at Sarah Cannon Research Institute in Nashville, soon to be followed by additional locations. For patients currently on Lorlatinib, NVL-655 provides a hope-filled option for those who test positive for certain mutations that are common upon progression on Lorlatinib. The trial is also open to a range of patients described below that are progressing after other treatment options.

Clinical TrialsKirk SmithJuly 18, 2022Clinical Trials, Nuvalent, ALKOVE-1